By Sean Marshall
This week the highlight would be a report from Grand View research outlining. The article produces by News Wire explained how the world Hemoglobin market will only raise in value. If the predictions are correct revenue due to research and cures towards blood born diseases will be expected to reach a U.S. dollar of “8.82 million.”
The article explains that this is all due to a realization that blood born illnesses are increasing in recent years and there are still no real solutions. The article goes so far as to explain that the “rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering drivers of the market.” It was also explained that “according to the WHO, hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant variation.”
The article also tackle issues that can cause complication to those with sickle cell disease as well as where sickle cell disease and other blood diseases. These factors included low level hygiene, low awareness levels and the inability to get to proper medical facilities.
Three important facts that the article highlighted about sickle cell that should be passed on were:
“The market for Sickle Cell Disease (SCD) was the largest with revenue valued at over USD 2,290.0 million in 2014. Rising prevalence of hemoglobinopathies and presence of strong product pipeline for sickle cell anemia such as HQK-1001 and Luspatercept are growth promoting factors of this market.”
“Genetic testing for diagnosis of sickle cell disorders is expected to witness lucrative growth over the forecast period. It is estimated to grow at a CAGR of around 7.0%. Increasing awareness levels among people coupled with government programs such as the National Sickle Cell Disease Control Program conducted by the WHO in Africa are anticipated to enhance the usage rates for diagnostic tests pertaining to SCD”
“Hydroxyurea was one of the dominating segments of the SCD therapy market owing to the presence of the FDA-approved drugs such as Droxia and Hydrea by Bristol Myers Squib. SCD. Thalassemia market holds an extensive product portfolio in pipeline and their expected commercialization is anticipated to drive market growth. For instance, The Ellis Lab is developing a gene therapy for SCD in collaboration with Dr.Victor Garcia.”
The original article is fantastic and should be read in detail. What I have presented is only a small portion of what I personally feel is important. I would highly recommend anyone in the sickle cell community or any blood born illness community to read the Grand view researching report or in the very least a news outlet reporting on it.
PR News wire’s article on Grandview's research can be found here: http://www.prnewswire.com/news-releases/hemoglobinopathies-market-worth-88-billion-by-2022-grand-view-research-inc-569930631.html
Unfortunately due to illness the sickle news will be postponed until next week.
By Sean Marshall
The news this week was short but included some positive outcomes. It was reported by the Birmingham Business Journal that Alabama University fulfilled their pledge in 2010 to donate $1 million. It may have taken six years but as of last December the goal was met.
What was reported is how the funds have been used. The first detail was that the funds will be providing “are for those patients and will also allow the clinic to hire a full-time social worker to the staff.” It was also mentioned that additional staff such as psychosocial services will be offered for both children and adults suffering from sickle cell disease.
Lastly a startling statistic was provided explaining that, “nearly 3,000 in Alabama struggle to manage sickle cell disease.” It does shed some light on to why the state university was so heavily invested in helping the clinic obtain positive results in the community.
The Original article can be found here: http://www.bizjournals.com/birmingham/news/2016/02/01/uab-receives-1m-in-funding-from-sickle-cell.html
If there are any comments questions or concerns please email us at firstname.lastname@example.org
This section is solely to let our Sickle Soldiers tell their story trials & tribulations alongside things they feel are wrong in the Sickle Cell Community